Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
**REVIEW**

**The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care**

FRANCESCO SAGLIO1, PATRICK J. HANLEY2 & CATHERINE M. BOLLARD2

1Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children’s Hospital, Turin, Italy, and 2Program for Cell Enhancement and Technologies for Immunotherapy, Sheikh Zayed Institute for Pediatric Surgical Innovation, and Center for Cancer and Immunology Research, Children’s National Medical Health System, Washington, DC, USA

**Abstract**

Adoptive immunotherapy—in particular, T-cell therapy—has recently emerged as a useful strategy with the potential to overcome many of the limitations of antiviral drugs for the treatment of viral complications after hematopoietic stem cell transplantation. In this review, we briefly summarize the current methods for virus-specific T-cell isolation or selection and we report results from clinical trials that have used these techniques, focusing specifically on the strategies aimed to broaden the application of this technology.

**Key Words:** immunotherapy, stem cell transplantation, T cell, virus

**Introduction**

Allogeneic hematopoietic stem cell transplantation (HSCT) has emerged as one of the best therapeutic options available for many patients with malignant and non-malignant diseases involving the hematopoietic system. The use of donors other than human leukocyte antigen (HLA)-matched siblings requires the depletion of host-attacking donor T cells to prevent graft-versus-host disease (GvHD). The broader use of alternative stem cell donor sources, such as unrelated donors, haploidentical related donors and umbilical cord blood (CB) have, however, resulted in an increased incidence of viral infections caused by the T-cell depletion strategies required to prevent GvHD. As a result, infection is one of the main causes of transplant-related mortality and morbidity in this setting (1).

Cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus (Adv) infections are particularly frequent among HSCT recipients and are often described as important risk factors affecting prognosis after HSCT (2–4). Although the introduction of sensitive viral screening techniques and pre-emptive treatment strategies have reduced deaths related to these complications, current antiviral drugs have some important limitations. First, depending on the drug, antiviral pharmacotherapy can result in bone marrow suppression and substantial toxicities (5,6) that are difficult to manage in patients who have undergone intense chemotherapy and radiation. Second, effective antiviral drugs do exist for CMV and EBV and can be beneficial, but the effectiveness of these agents in patients with Adv infection has only been suggested by non-randomized and uncontrolled clinical trials, and, in our experience, they are often not effective (7). Antiviral drugs—especially those used for CMV—can lead to late-onset CMV disease. Once the antiviral pharmacotherapy is removed, the late-onset CMV may be worse than the original reactivation because the use of these agents can delay virus-specific immune recovery (2). As a result, patients with viral complications may require multiple treatment courses, which is not only expensive, but drug resistance may also occur. In the case of
Figure 1. GMP-applicable approaches for the generation of virus-specific T cells. (A) In the classic *ex vivo* expansion, T cells are combined with APCs that have been transduced with either a viral vector or plasmids encoding the antigens of interest. The APCs are used to stimulate the T cells until cells of sufficient specificity and number have been expanded. (B) To prepare virus-specific T cells with the use of multimers, T cells are incubated with multimers that mimic the peptide:MHC binding of an APC. The T cells that bind the multimer are then isolated with the use of magnetic beads or fluorescence-activated cell sorting. (C) In the gamma-capture technique, T cells are activated use of the
CMV, 94% of strains resistant to the common antiviral drug ganciclovir are caused by mutations in the UL97 gene. Furthermore, Nichols et al. (8) reported that despite the use of antiviral drugs, approximately one third of transplant recipients had increasing viral loads after initiating antiviral therapy. Hence, one of the most attractive and innovative approaches to overcome the limits of current antiviral pharmacotherapies is adoptive immunotherapy with the use of virus-specific T cells.

Current methodologies for virus-specific T-cell generation or selection

Over the past 20 years, there has been an increasing use of virus-specific adoptive T-cell therapies in which donor-derived virus-specific T lymphocytes are administered to patients with the primary goal of counteracting the effects of uncontrolled viral replication in immunosuppressed patients after HSCT. To optimize this approach, numerous in vitro studies have been conducted by various groups in an attempt to identify the best methodology for the expansion or selection of virus-specific T lymphocytes for clinical use (Figure 1, Table I) (9–15).

The first experiences with the use of antiviral adoptive immunotherapy used T cells expanded with CMV-infected fibroblasts (16,17) or CMV lysate (18,19). Although effective, this made them difficult to export because of the regulatory hurdles required for such a production. Indeed, the expansion of virus-specific T cells often requires clean rooms, quality control, quality assurance, release testing and documentation to meet current good manufacturing practice (cGMP) compliance. One of the first cGMP-compliant strategies reported for the manufacture of virus-specific T cells was the selection of virus-specific T cells from bulk donors' T lymphocytes by tetramer selection (9). The advantages of this method were the rapid availability of the T cells and the ease of the selection process, which does not require antigen-presenting cells (APCs), exogenous cytokines or extended ex vivo manipulation and can be performed with the use of closed-system devices outside of a dedicated clean room or GMP facility. However, tetramer-mediated selection only selects T cells specific for a single HLA-restricted epitope of a single virus (in this case CMV) and is generally only available for donors with the most common of HLA types. Although sometimes effective, focusing the antiviral response to one epitope leaves the patient vulnerable to antigenic escape, as has been observed clinically for EBV (20,21).

Another method to isolate virus-specific T cells is by immunomagnetically selecting T cells that secrete interferon (IFN)-γ in response to virus-derived overlapping peptides (10,22). This technique is advantageous because the cells are rapidly available and do not require extensive manipulation while still targeting entire antigens or viruses, depending on the stimuli. However, the selection of unexpanded T cells has been associated with GvHD, and, as with the tetramer technology, this option is currently only available for donors who are seropositive for the virus being targeted.

Another GMP-applicable method to generate virus-specific T cells involves the stimulation of peripheral blood mononuclear cells (PBMC) with APCs. This approach was investigated in the 1990s to generate EBV-specific cytotoxic T cells (CTL) by stimulating PBMC with EBV-transformed lymphoblastoid cell lines (LCL) (23) and was later modified to include a first stimulation with dendritic cells transduced with clinical-grade adenoviral vectors expressing viral antigens for EBV or CMV, thus expanding the antiviral specificity of the CTL (11). Furthermore, CTL expanded in this way enable T cells to recognize three viruses (EBV [from the LCL], CMV [from the engineered adenoviral vector], and adenovirus [from the adenoviral vector]) in a single culture with a very high specificity starting from a relatively low blood volume (50–60 mL). The limitation of this approach is that it is time-consuming (up to 3 months), requires the use of a clinical grade viral vector, which is expensive, and can be a major regulatory hurdle.

To remove the need for viral vectors, more recent approaches have used dendritic cells that were either nucleofected with plasmid DNA encoding different viral antigens or pulsed with overlapping peptides for viral antigens to stimulate and expand multi-virus-specific T cells. After only a single stimulation (a total of approximately 10–17 d), the CTL were frozen and ready for use pending the release testing (12,13).

Despite the manufacturing advances made for the generation of virus-specific T cells, none of the approaches described above are able to expand virus-specific T cells from donors who are virus-seronegative. This is a limitation because one of the biggest risks for viral infection (excluding immune suppression) is when the graft does not contain a specific T-memory compartment (such as in cord blood or seronegative adult donors) and the recipient is latently infected by these pathogens (24–26). To
address this unmet need, several groups have evaluated strategies to stimulate the naive T cells present in cord blood (27–31). Furthermore, with the use of the G-Rex gas-permeable device (32), it was possible to expand cord blood–derived T cells to numbers sufficient for clinical use, demonstrating for the first time that it is possible to generate multivirus-specific T cells in a virus-inexperienced setting in a cGMP-applicable manner (14,33).

**Clinical experiences with virus-specific CTL**

**Treating cytomegalovirus**

The first clinical protocols whereby CMV-specific T cells were cultured from hematopoietic stem cells donors and then transferred to the recipients were successfully performed in the early 1990s: The Seattle group treated 14 HSCT recipients with CMV-specific clones generated from stem cell donors observing neither CMV viremia increase or CMV disease in any of them (16,17).

In an attempt to more rapidly generate CMV-specific T cells, several groups have explored strategies that limit the ex vivo expansion time. Peggs et al. from the University College of London generated CMV-specific T cells by selecting IFN-γ–secreting T cells after exposure to viral antigens. They treated 18 matched related donor (MRD) and matched unrelated donor (MUD) HSCT recipients both as prophylaxis and as pre-emptive therapy. The results of this trial were promising for patients treated as prophylaxis (six of seven patients did not have CMV re-activation after CMV-specific T-cell infusion), but this approach appeared to be less efficient in clearing ongoing infections, because nine of 11 patients treated pre-emptively still required additional antiviral drugs. Moreover, in this trial, GvHD was observed in multiple patients, probably as a consequence of selecting highly activated T cells (10) (Table II).

The use of tetramer-selected T cells was first reported by Cobbold et al. (9). They treated nine patients who had undergone matched-related donor (MRD) and matched unrelated donor (MUD) HSCTs and who had CMV re-activation after HSCT. After the administration of tetramer-selected CMV-specific T cells, eight of nine patients cleared the virus, but two cases of GvHD were observed (9). These data are confirmed by several other clinical trials showing that this therapy is safe and often able to overcome some of the limitations of antiviral drugs (34,35).

**Treating adenovirus**

Feuchtinger et al. (36,37) reported the first experience in which AdV-specific T cells were used to treat AdV infection in patients undergoing HSCT. In their clinical trial, nine patients underwent MRD,
MUD, mismatched unrelated donor (MMUD) or haplo-HSCT and had development of either refractory AdV infection or were unresponsive to antiviral drugs; these patients were treated with AdV-specific T cells: five patients had spontaneous clearance of viremia, and only one case of already-established GvHD re-aggravation was reported. In one recent study, Qasim et al. (38) treated pediatric patients by selecting IFN$\gamma$ secreting T cells after exposure to hexon. However, two of five patients did not have detectable hexon-specific T cells, and third-party donors were needed (38) (Table III).

**Treating EBV**

The opportunity to readily activate EBV-specific T cells from healthy EBV-seropositive HSCT donors with the use of LCL as APCs and the seriousness of this infection in HSCT recipients (post-transplant lymphoproliferative disease, PTLD) also made EBV one of the first targets suitable for adoptive immunotherapy (39,40) (Table IV). In a multi-institutional study enrolling 114 patients undergoing MRD, MUD and haplo-HSCT, none of the 101 patients who received donor-derived EBV-specific CTLs both as prophylaxis and as pre-emptive therapy had development of PTLD, and no cases of de novo GvHD occurred after CTL infusion (41). Historically, in patients who received T-cell–depleted grafts with similar conditioning regimens, the rate of PLTD was approximately 11%. Furthermore, of the 13 patients who were treated for overt PTLD, 11 achieved complete remission that was sustained without recurrence. The most significant adverse effects seen were localized but reversible and included swelling at sites of disease during the therapeutic response in four patients with bulky disease at the time of T-cell therapy. In addition, the group at Memorial Sloan-Kettering Cancer Center reported the results of another large study that used EBV-specific CTLs for the treatment of PTLD: 47 patients with HSCT were treated for PTLD with donor-derived or third-party–derived EBV CTLs, with an overall response rate of 68% without evidence of de novo or recurrent GvHD (42). Other smaller studies reported similar results in terms of both efficacy and safety of EBV-specific CTLs obtained by LCL stimulation (43,44). Hence, the adoptive transfer of EBV-specific T cells is a safe and effective strategy both in the prophylaxis or therapeutic setting (45).

**Treating multiple viruses**

To further broaden the specificity of CTL, several groups have explored the use of multi-virus–specific T-cells, including T cells targeting EBV and Adv (46) or CMV and Adv (47) or CMV, Ad and EBV (11,48). One large study from Australia demonstrated the efficacy and the safety of infusing bi-virus–specific T cells to 50 MRD and MUD HSCT recipients. These patients received T cells specific for CMV (with or without adenovirus) as prophylaxis and observed the same incidence of GvHD and a statistically significant reduced incidence of CMV re-activation compared with a
Table III. T-cell therapy for adenovirus infection after stem cell transplant.

| Reference                  | n  | HSCT type       | Strategy               | End points          | Results                                                                 |
|---------------------------|----|-----------------|------------------------|---------------------|-------------------------------------------------------------------------|
| Feuchtinger, 2006 (38)    | 9  | MRD, MUD, MMUD, haplo | Treatment (refractory/unresponsive to antiviral drugs) | Safety Efficacy CTL expansion | > 1 case of aggravated pre-existing GvHD  |
|                           |    |                  |                        |                     | > AdV-specific T cells detectable in 5/6 patients                      |
|                           |    |                  |                        |                     | > 5/6 patients cleared AdV                                             |
|                           |    |                  |                        |                     | > No GvHD                                                              |
|                           |    |                  |                        |                     | > 11/12 patients with AdV cleared the virus                           |
|                           |    |                  |                        |                     | > Rise in AdV-specific T cells in patients with AdV infection         |
| Leen, 2006 (11) and Hanley 2013 (15) | 34 | MRD, MUD, haplo | Prophylaxis            | Safety Efficacy CTL expansion | > No GvHD                                                             |
|                           |    |                  |                        |                     | > 10 patients remained AdV-free                                       |
|                           |    |                  |                        |                     | > 2 patients had AdV and cleared after CTL infusion                  |
|                           |    |                  |                        |                     | > Rise in AdV-specific T cells only in patients with AdV infection   |
| Leen, 2009 (46)           | 13 | MUD, haplo       | Prophylaxis (12)       | Safety Efficacy CTL expansion | > No de novo GvHD                                                   |
|                           |    |                  | Treatment (1)          |                     | > 6 patients remained AdV-free                                       |
|                           |    |                  |                        |                     | > 1 patient had AdV infection and cleared spontaneously             |
| Hanley, 2012 (51)         | 7  | Cord blood       | Prophylaxis treatment  | Safety Efficacy CTL expansion | > Detectable AdV-specific T cells in patient with AdV infection    |

Table IV. T-cell therapy studies for EBV reactivation and post-transplant lymphoproliferative disorder occurring after HSCT.

| Reference                  | n  | HSCT type       | Strategy               | End points          | Results                                                                 |
|---------------------------|----|-----------------|------------------------|---------------------|-------------------------------------------------------------------------|
| Gustafsson, 2000 (43)     | 9  | MRD, MUD, MMUD  | Pre-emptive therapy    | Antiviral effect    | > 2–4 log decrease in EBV viral load in 4 patients                      |
|                           |    |                  |                        |                     | > EBV stabilization in 1 patient                                       |
|                           |    |                  |                        |                     | > 1 case of progressive PTLD                                           |
|                           |    |                  |                        |                     | > No GvHD                                                              |
|                           |    |                  |                        |                     | > 10/10 patients with high EBV load cleared the virus                 |
|                           |    |                  |                        |                     | > Up to 5-fold increase in EBV-specific T cells                       |
|                           |    |                  |                        |                     | > No adverse events                                                   |
|                           |    |                  |                        |                     | > EBV DNA cleared in all patients                                      |
| Leen, 2006 (11) and Hanley 2013 (15) | 34 | MRD, MUD, haplo | Pre-emptive therapy PTLD treatment | Safety Efficacy CTL expansion | > No de novo GvHD                                                   |
|                           |    |                  |                        |                     | > 9 patients remained EBV-free                                       |
|                           |    |                  |                        |                     | > 3 patients had increased viremia, cleared spontaneously             |
| Comoli, 2007 (44)         | 4  | Haplo            | Prophylaxis            | Safety Efficacy     | > No de novo GvHD                                                   |
|                           |    |                  |                        |                     | > 6 patients remained EBV-free                                       |
|                           |    |                  |                        |                     | > 1 patient had increased EBV                                         |
| Heslop, 2010 (45)         | 114| MRD, MUD, haplo | Prophylaxis (101 patients) PTLD treatment (13 patients) | Safety Efficacy | > 8 patients had GvHD recurrence after CTL                          |
|                           |    |                  |                        |                     | > 0% PTLD incidence versus 11% in patients treated in same protocol without CTL |
|                           |    |                  |                        |                     | > 85% of patients affected by PTLD achieved CR with CTL              |
|                           |    |                  |                        |                     | > No GvHD                                                              |
|                           |    |                  |                        |                     | > 0% patients engrafted using only 80% of the cord blood unit        |
|                           |    |                  |                        |                     | > 7/7 patients engrafted using only 80% of the cord blood unit        |
| Hanley, 2012 (51)         | 7  | Cord blood       | Prophylaxis treatment  | Safety Efficacy CTL expansion | > Detectable EBV-specific T cells                                    |
blood (51). Detection of EBV-specific T cells in the peripheral blood that coincided with the detection of EBV-specific T cells in the peripheral blood (51).

In addition to CMV, EBV and Adv, HSCT recipients are also susceptible to other viral infections such as BK virus, JC virus, human herpes virus (HHV)6, HHV7, influenza, para-influenza, coronavirus, and human respiratory syncytial virus, all of which may cause severe morbidity and mortality (50). To extend this approach to others viruses, the group at Baylor College of Medicine described a method by which it is possible to rapidly generate a single preparation of polyclonal (CD4+ and CD8+) T cells that are specific for seven viruses (EBV, CMV, Adv, BK, HHV6, human respiratory syncytial virus and influenza) frequently described as important risk factors affecting prognosis after HSCT (13). These broadly virus-specific T cells are now being evaluated clinically (ClinicalTrials.gov Identifier NCT01570283).

In all of the above-mentioned clinical trials, one of the inclusion criteria was the availability of a seropositive donor. The clinical experience of T-cell—adoptive immunotherapy from seronegative donors is still limited, but cord blood—derived CTLs are currently being tested in a phase I clinical trial. Of nine patients receiving multi-virus-specific CTL (CMV, EBV and Adv), only three patients had viral reactivations. One patient had both CMV reactivation and adenovirus infection. After T-cell infusion, there was an increase in CMV-specific T cells detected in the peripheral blood that coincided with a decrease in CMV viral load. The patient also successfully cleared the adenovirus infection without additional antiviral therapy. Two patients had EBV reactivation or infection either before or soon after CTL infusion that was controlled without additional therapy, coinciding with the detection of EBV-specific T cells in the peripheral blood (51).

**Strategies to broaden the application of antiviral adoptive immunotherapy**

The widespread use of T cells to prevent or treat viral complications occurring after HSCT is mainly limited by their relatively long production time and by the complexity of the production process itself, which limits the therapy to a relatively small number of centers. Several groups have investigated different approaches to overcome these limitations, and several strategies have emerged as potentially suitable for clinical investigation or are already being investigated in ongoing studies. Tetramer selection and IFN-γ—secreting T-cell isolation are by themselves two encouraging approaches in terms of handiness and reproducibility, but, as mentioned above, they still have some pitfalls that emerged when these approaches were tested clinically (9,10,52–54).

Another potential strategy to broaden the application of virus-specific T cells is the use of third-party T cells. The generation and the banking of HLA-typed virus-specific T-cell lines ready to be infused could represent an option for patients suitable for antiviral T-cell—based immunotherapy but for whom the clinical condition requires a prompt intervention (Table V). This “off-the-shelf” approach was initially evaluated by Haque et al. (55), who treated 33 patients (HSCT recipients and solid organ transplantation recipients) with third-party EBV-specific CTL for PTLD. They observed overall response rates of 64% at 5 weeks and 52% at 6 months, with no cases of GvHD or graft rejection. The best results were observed in patients who received donor T cells that were best HLA-matched with the recipient (55). The Memorial Sloan Kettering Group also confirmed the safety of this strategy describing their results comparing the use of third-party EBV-specific CTLs with the use of donor lymphocytes infusion (DLI) in patients who had development of PTLD after CB HSCT. Whereas the response rate was similar in both groups, GvHD occurred more frequently in patients treated with DLI (56). In 2011, Quasim et al. (57) also described the results of a trial enrolling patients with development of Adv infection after MUD HSCT treated with third-party Adv-specific T cells, highlighting a high risk of GvHD development, but, in this case, T cells were generated by means of the IFN-γ capture technology, which may increase the risk for the presence of alloreactive T cells in the infused product.

Finally, a recent multi-center study used banked third-party multi-virus—specific T cells and showed that this is a feasible and safe approach to rapidly treat multiple viral infections occurring after...
This study showed that a clinical effect is possible even when the CTL donor and transplant recipient share a single HLA locus. The caveat is that the shared allele must be known to present a known and effective epitope of the virus, meaning that extensive in vitro characterization of the CTL lines must be performed by laboratories with extensive expertise (58). Nevertheless, this approach resulted in a 74% complete or partial response rate. Importantly, 50 patients with an array of HLA types were successfully treated with the use of only 18 cell lines. Furthermore, this approach demonstrated that an in-depth characterization of the CTL product not only serves as a measure of potency but can also be used to customize a treatment for each patient through the use of the banked T cells.

**Moving beyond phase 1**

The age of antiviral immunotherapy being a “boutique” therapy is, we hope, coming to an end. Since the first clinical trial testing the efficacy of these cells, advances have been trending toward making the technology faster, more streamlined, standardized and more affordable. To move beyond phase I/II, later phase clinical trials are typically sponsored by large pharmaceutical companies interested in marketing their product, and this type of partnership is essential for cell therapy to continue to move beyond early-phase clinical trials. From an academic perspective, laboratories must continue to innovate and make laborious processes more efficient, cost effective and more broadly applicable. Beyond processing, alternative transduction methods such as transposons and overlapping peptides must be optimized to limit the use of viral vectors (59).

Finally, although third-party CTL appear to be the most appealing way to manufacture CTL and administer them to patients, these CTL will only become the standard of care if manufacturing technologies continue to improve. The use of gas-permeable culture device technology represents a significant advance for the rapid expansion of T cells, but these devices still require multiple manipulations that are exposed to the environment (increasing the risk of contamination) and must be performed in biosafety cabinets. Large-scale cultures bags and devices are now being produced (60), but whether they can support complex expansions such as those required for antigen-specific T cells remain to be tested.

**Conclusions**

With improved detection techniques and the introduction of pre-emptive strategies, the prognosis for patients with viral complications after HSCT has improved, but pharmacotherapeutic agents still have some important pitfalls. One of most investigated and promising approaches to overcome some of the limitations of antiviral drugs is adoptive immunotherapy with the use of virus-specific T cells. At the moment, different virus-specific T-cell isolation/generation techniques are available: each has its own advantages and limitations, and none of them has been shown to be superior in pre-clinical studies. To move virus-specific T-cell therapy to the mainstream, larger studies are necessary to simplify the manufacturing process and to extend the availability to all HSCT recipients, irrespective of their donor status. Rapid T-cell generation and third-party–derived T-cell infusion are being currently investigated as potential solution to overcome some of the limitations regarding availability, but, in the meantime, other solutions (ie, CTL generation from virus-naive sources) should also continue to be tested to further broaden the application of this approach.

| Reference | n  | Target       | Type of HSCT         | Serious Adverse Events | Results                                      |
|------------|----|--------------|----------------------|------------------------|----------------------------------------------|
| Barker, 2010 (56) and Doubrovina, 2012 (42) | 5  | EBV          | Cord blood           | None                   | >4 patients achieved CR                      |
|           |    |              |                      |                        | >1 patient had disease progression            |
|           |    |              |                      |                        | >CR                                          |
|           |    |              |                      |                        | Subsequent relapse treated with 2nd CTL infusion |
| Uhlin, 2010 (61) | 1  | EBV          | Cord blood           | None                   | >82% CR and partial remission                |
| Leen, 2010 (62) and Leen, 2012 (63) | 44 | EBV, CMV, AdV | MRD, MUD, cord blood | >=8 cases of GvHD after CTL (2 cases of de novo GvHD and 6 cases of GvHD recurrence) |                              |
| Qasim, 2011 (57) | 1  | Adv          | MMUD                 | Grade II-IV GvHD (skin, liver) | >AdV clearance                               |
|           |    |              |                      |                        | Patient died of CMV pneumonia               |
Acknowledgments

This work was supported by Solidarity Banks Onlus awarded to FS, a postdoctoral fellowship, PF-13—046—01-LIB, from the American Cancer Society awarded to PJH, and CPRIT RO1 RP100469, and NCI PO1 CA148600—02 awards to CMB.

Disclosure of interests: The authors have no commercial, proprietary, or financial interest in the products or companies described in this article.

References

1. Kennedy-Nasser AA, Bollard CM, Myers GD, Leung KS, Gottschalk S, Zhang Y, et al. Comparable outcome of alternate donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Blood Marrow Transplant. 2008;14:1245—52.

2. Bocek M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101:407—14.

3. Brunstein CG, Weisford DJ, DeFor T, Tolar J, van Burik JA, et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood. 2006;108:2874—80.

4. Myers GD, Krance RA, Weiss H, Kuehnle I, Demmler G, Heslop HE, et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant. 2005;36:1001—8.

5. Salzberger B, Bowden RA, Hackman RC, Davis C, Bocek M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood. 1997;90:2502—8.

6. Kumar D, Humar A. Cytomegalovirus prophylaxis: how long is enough? Nat Rev Nephrol. 2010;6:13—4.

7. Matthies-Martin S, Feuchtiger T, Shaw PJ, Engelhard H, Hirsch HH, Cordonnier C, et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis. 2012;14:555—63.

8. Nichols WG, Corey L, Gooley T, Drew WL, Miner R, Huang M, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood. 2001;97:867—74.

9. Cobbold M, Khan N, Pourghorabeh B, Taura S, McDonald D, Osman H, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202:379—86.

10. Peggs KS, Thomson K, Samuel E, Dyer G, Armoogum J, Chakraverty R, et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis. 2011;52:49—57.

11. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12:1160—6.

12. Gerdemann U, Christin AS, Vera JF, Ramos CA, Fujita Y, Liu H, et al. Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther. 2009;17:1616—23.

13. Gerdemann U, Keirnan JM, Katari UL, Yanagisawa R, Christin AS, Huye LE, et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012;20:1622—32.

14. Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanjevic M, Khalil M, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009;114:1958—67.

15. Hanley PJ, Leen AM, Gee AP, Leung K, Martinez C, Krance R, et al. Multi-virus-specific T-cell therapy for patients after hematopoietic stem cell and cord blood transplantation. ASH Annual Meeting Abstracts. 2013.

16. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257:38—41.

17. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas RD, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038—44.

18. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99:3916—22.

19. Peggs KS, Verfuerth S, Pizzey A, Chow SL, Thomson K, Mackinnon S. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clin Infect Dis. 2009;49:1851—60.

20. Hanley PJ, Shaffer DR, Cruz CR, Ku S, Tzou B, Liu H, et al. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy. 2011;13:976—86.

21. Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, et al. Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001;97:835—43.

22. Moosmann A, Bigalke I, Fischer J, Schirrmann L, Kasten J, Tischer J, et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood. 2010;115:2960—70.

23. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345:9—13.

24. Ugarte-Torres A, Hoehn-Petersen M, Liu Y, Zhou F, Williamson TS, Quinlan D, et al. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2011;17:574—85.

25. Jaskula E, Bochenska J, Kocwin E, Tarnowska A, Lange A. CMV serostatus of donor-recipient pairs influences the risk of CMV infection/reactivation in HSCT patients. Bone Marrow Res. 2012;2012:375075.

26. Merindol N, Salem Fourati I, Brito RM, Grenier AJ, Charrier E, Cordeiro P, et al. Reconstitution of protective
55. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110: 1123–31.

56. Barker JN, Doubrovina E, Sauter C, Jaroscak JJ, Perales MA, Doubrovin M, et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood. 2010;116:5045–9.

57. Qasim W, Derniame S, Gilmour K, Chiesa R, Weber M, Adams S, et al. Third-party virus-specific T cells eradicate adenoviraemia but trigger bystander graft-versus-host disease. Br J Haematol. 2011;154:150–3.

58. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121:5113–23.

59. Nakazawa Y, Huye LE, Salsman VS, Leen AM, Ahmed N, Rollins L, et al. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther. 2011;19:2133–43.

60. Singh V. Disposable bioreactor for cell culture using wave-induced agitation. Cytotechnology. 1999 Jul;30(1–3):149–58.

61. Uhlin M, Okas M, Gertow J, Uzunel M, Brismar TB, Mattsson J. A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol Immunother. 2010;59:473–7.

62. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, et al. Most closely HLA-matched allogeneic virus specific cytotoxic T-lymphocytes (CTL) to treat persistent reactivation or infection with adenovirus, CMV and EBV after hematopoietic stem cell transplantation (HSCT). ASH Annual Meeting Abstracts 2010, November 19. 2010;116:829.

63. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, et al. Multicenter study of “off-the-shelf” third party virus-specific T cells (VSTs) to treat adenovirus (Adv), cytomegalovirus (CMV) or Epstein Barr Virus (EBV) infection after hematopoietic stem cell transplantation (HSCT). ASH Annual Meeting Abstracts, 2012 November 16. 2012;120:457.